Trial
NCT01808950
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Spirig Pharma Ltd.
Collaborators
—
Condition
Nodular Basal Cell Carcinoma
Intervention
0.06% Resiquimod Gel - A
Why stopped
safety issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-22